arrow
J

Judith S. Currier

university of california los angeles
H指数:64
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

REPRIEVE研究人群中的高血压患病率及控制情况:一项二次分析的结果

2026-08-200
OAAI
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution

吸入型干扰素-β1a对SARS-CoV-2多样性和进化的影响

2026-07-070
PRE
The Effect of Low Dose Methotrexate on Arterial Inflammation in Persons Living with Human Immunodeficiency Virus. A double-blind randomized placebo-controlled pilot trial.

低剂量甲氨蝶呤对人类免疫缺陷病毒感染者动脉炎症的影响。一项双盲随机安慰剂对照的初步试验。

2025-12-110
PRE
Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness

针对在津巴布韦经历依从性障碍的HIV阳性哺乳期妇女的长效抗逆转录病毒疗法:模型分析其临床影响和成本效益

2025-12-010
OA
High HBV seroprotection rates in infants born to people with HIV and HBV infection in sub-Saharan Africa

撒哈拉以南非洲地区,HIV和HBV感染者的婴儿具有高HBV血清保护率。

2025-11-210
OAAI
Statin-dependent and-independent pathways are associated with major adverse cardiovascular events in people with HIV

他汀依赖性和非依赖性通路与HIV感染者中的主要不良心血管事件相关。

2025-11-170
OAAI
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2

基于PCE、PREVENT和SCORE2对全球HIV感染者心血管疾病预防队列的风险评估

2025-11-011
OAAI
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

肌肉内或静脉内给予抗病毒单克隆抗体疗法快速清除可培养的SARS-CoV-2

2025-09-010
OAAI
Inflammation, Antiretroviral Therapy Continuation, and HIV Disease Progression in Postpartum Women With HIV

炎症、抗逆转录病毒疗法持续应用及HIV感染者产后疾病进展

2025-08-250
PRE
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process

建立长效注射用卡博格韦和 rilpivirine 治疗的病毒学失败和停药共享定义(CONSENSUS-LAI 研究):一项国际调查和德尔菲过程

2025-08-040
OAAI
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis

抗逆转录病毒药物对REPRIEVE试验中主要不良心血管事件的影响:一项纵向队列分析

2025-06-040
PRE
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial

匹他伐他汀对HIV感染者表观遗传衰老生物标志物的影响:REPRIEVE试验的试点亚组研究

2025-06-013
PRE
Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With Human Immunodeficiency Virus (HIV)

影响人类免疫缺陷病毒(HIV)感染者全球心血管疾病(CVD)预防队列中心血管事件风险的因素

2025-04-250
PRE
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
2025-04-010
OAAI
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
2025-02-171
OAAI
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Tixagevimab/cilgavimab 或安慰剂用于 ACTIV-2 研究:安全性、药代动力学及中和抗体和抗药抗体

2025-02-010
OAAI